Metagenomi Therapeutics
43 hedge funds and large institutions have $7.45M invested in Metagenomi Therapeutics in 2026 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 12 increasing their positions, 13 reducing their positions, and 8 closing their positions.
0.55% less ownership
Funds ownership: 17.18% → 16.64% (-0.55%)
8% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 13
10% less funds holding
Funds holding: 48 → 43 (-5)
14% less capital invested
Capital invested by funds: $8.65M → $7.45M (-$1.2M)
50% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 8
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
+$237K |
| 2 |
MAM
Marquette Asset Management
Minneapolis,
Minnesota
|
+$96.5K |
| 3 |
Man Group
London,
United Kingdom
|
+$40.8K |
| 4 |
BlackRock
New York
|
+$36.8K |
| 5 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
+$26.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$297K |
| 2 |
Jane Street
New York
|
-$151K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$93K |
| 4 |
Millennium Management
New York
|
-$75K |
| 5 |
Renaissance Technologies
New York
|
-$60.9K |
MGX Hedge Fund Activity: Q2 2026 in Review
43 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Metagenomi Therapeutics (MGX) for Q2 2026, worth a combined $7.45M — down 14% from $8.65M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of MGX and 4 opened new positions — a net loss of 4 holders — while 13 trimmed existing stakes and 12 added.
The largest buyer was Wells Fargo, adding an estimated $237K. The largest seller was Jacobs Levy Equity Management, cutting an estimated $297K.
- 43 institutional investors held Metagenomi Therapeutics (MGX) as of Q2 2026, down from 48 in Q1 2026.
- Funds reported $7.45M of Metagenomi Therapeutics stock for Q2 2026, down 14% quarter-over-quarter.
- 4 funds opened new Metagenomi Therapeutics positions in Q2 2026 and 8 closed out, a net change of -4 holders.
- The largest Metagenomi Therapeutics buyer in Q2 2026 was Wells Fargo, an estimated $237K added.
- The largest Metagenomi Therapeutics seller in Q2 2026 was Jacobs Levy Equity Management, an estimated $297K sold.
Based on aggregated 13F filings for Q2 2026.